The KRESLADI approval and PRV monetization remove near-term financing risk and de-risk the pipeline; watch for Danon disease program update in H2 2026 as next major catalyst. Market cap of $1M for the warrant (RCKTW) means price swings can be extreme on low volume.
Price Chart
Executive Summary
Rocket Pharmaceuticals reported Q1 2026 net loss of -$47.6M (-$0.42/share), improving from -$61.3M (-$0.56) a year ago. The key catalyst was FDA accelerated approval of KRESLADI for severe LAD-I in March, followed by monetization of the resulting Rare Pediatric Disease Priority Review Voucher for $180M in April, extending cash runway into Q2 2028. The Danon disease pivotal Phase 2 trial has resumed dosing; an update is expected in H2 2026.
Key Financial Metrics
Key Facts
- FDA granted accelerated approval for KRESLADI in severe LAD-I (March 2026)
- PRV sold for $180M on April 28, 2026 (non-dilutive capital)
- Pro forma cash ~$322.6M (including PRV proceeds); runway into Q2 2028
- Q1 2026 net loss -$47.6M (-$0.42/share) vs -$61.3M (-$0.56) YoY
- Danon disease Phase 2 trial dosing resumed; program update in H2 2026
- No revenue reported (pre-commercial stage)
- 109.1M shares outstanding as of March 31, 2026
Financial Impact
PRV sale adds $180M cash; net loss improved by $13.7M YoY; cash burn reduction extends runway 4+ quarters
Risk Factors
- No commercial revenue yet; KRESLADI launch uptake uncertain
- Danon disease Phase 2 results could disappoint
- Additional clinical holds or safety signals in AAV programs
- Dilution risk from future equity raises (though cash extended)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-019573 |
| Document: ef20072739_8k.htm | 0001140361-26-019573 |
| Document: 0001140361-26-019573-index-headers.html | 0001140361-26-019573 |
| Document: 0001140361-26-019573-index.html | 0001140361-26-019573 |
| Document: 0001140361-26-019573.txt | 0001140361-26-019573 |
| 8-K Data (Synthetic) | 0001140361-26-019573 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 13, 2026 20w ago | 144 | $0.0193 $0.0193 | · 0.00% | ▲ +0.61% | — |
May 7, 2026 21w ago | 8-K | $0.0193 $0.0193 | · 0.00% | ▼ −0.02% | — |
May 7, 2026 21w ago | 144 | $0.0193 $0.0193 | · 0.00% | ▼ −3.14% | — |
Apr 28, 2026 22w ago | 8-K | $0.0193 $0.0193 | · 0.00% | ▼ −5.46% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access